<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287664</url>
  </required_header>
  <id_info>
    <org_study_id>TAHRS</org_study_id>
    <nct_id>NCT00287664</nct_id>
  </id_info>
  <brief_title>Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin</brief_title>
  <official_title>Terlipressin as Treatment of Patients With Cirrhosis and Hepatorenal Syndrome. Effect on Survival and Renal Function. Multicenter, Randomized and Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grant from Education Ministery from 2001-2004.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <brief_summary>
    <textblock>
      Hepatorenal syndrome is a common complication of cirrhotic patients. The prognosis of
      patients with HRS is very poor. It have been demonstrated that vasoconstrictors agents
      (Terlipressin) plus albumin are effective in the reversal of the treatment. However, previous
      studies are pilot studies and they are not able to give information about an improvement in
      survival. This comparative randomized study was delineated to test the efficacy of
      terlipressin on survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 3
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    because in a preliminary analysis we would need 1000 patients per group to achieve
    significative differences in the main end point.
  </why_stopped>
  <start_date>February 2002</start_date>
  <completion_date>September 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <enrollment>100</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Hepatorenal Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terlipressin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with HRS type 1 or 2 with serum creatinine &gt;2 mg/dL

          2. Age between 18 and 75 years

          3. Written informed consent.

          4. Absence of exclusion criteria

        Exclusion Criteria:

          1. Hepatocarcinoma (3 nodules greater than 3 cm or 1 nodule &gt; than 5 cm)

          2. Active infection with systemic inflammatory response syndrome

          3. Respiratory or cardiac dysfunction.

          4. Arteriopathy.

          5. Ischemic cardiopathy.

          6. Arterial hypertension ( &gt;140/90 mmHg during hospitalization )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pere Gines, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chair of Liver Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2006</study_first_submitted>
  <study_first_submitted_qc>February 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2006</study_first_posted>
  <last_update_submitted>April 10, 2007</last_update_submitted>
  <last_update_submitted_qc>April 10, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2007</last_update_posted>
  <keyword>hepatorenal syndrome</keyword>
  <keyword>terlipressin</keyword>
  <keyword>albumin</keyword>
  <keyword>cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatorenal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

